MY134189A - Process for preparing crystalline form i of cabergoline - Google Patents

Process for preparing crystalline form i of cabergoline

Info

Publication number
MY134189A
MY134189A MYPI20011364A MYPI20011364A MY134189A MY 134189 A MY134189 A MY 134189A MY PI20011364 A MYPI20011364 A MY PI20011364A MY PI20011364 A MYPI20011364 A MY PI20011364A MY 134189 A MY134189 A MY 134189A
Authority
MY
Malaysia
Prior art keywords
cabergoline
crystalline form
preparing crystalline
intermadiate
toluene
Prior art date
Application number
MYPI20011364A
Other languages
English (en)
Inventor
Tomasi Attilio
Magenes Stefania
Ramella Giuliano
Ungari Mario
Pallanza Gianfranco
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9888433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY134189(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of MY134189A publication Critical patent/MY134189A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI20011364A 2000-03-24 2001-03-22 Process for preparing crystalline form i of cabergoline MY134189A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0007308.0A GB0007308D0 (en) 2000-03-24 2000-03-24 Process for preparing crystalline form | of cabergoline

Publications (1)

Publication Number Publication Date
MY134189A true MY134189A (en) 2007-11-30

Family

ID=9888433

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20011364A MY134189A (en) 2000-03-24 2001-03-22 Process for preparing crystalline form i of cabergoline

Country Status (31)

Country Link
US (2) US6727363B2 (https=)
EP (1) EP1272489B1 (https=)
JP (1) JP4184666B2 (https=)
KR (1) KR100827558B1 (https=)
CN (1) CN1188412C (https=)
AR (1) AR032449A1 (https=)
AT (1) ATE250601T1 (https=)
AU (2) AU780747B2 (https=)
BR (1) BR0109507A (https=)
CA (1) CA2402836A1 (https=)
CZ (1) CZ20023176A3 (https=)
DE (1) DE60100858T2 (https=)
DK (1) DK1272489T3 (https=)
EA (1) EA005928B1 (https=)
EE (1) EE05088B1 (https=)
ES (1) ES2208602T3 (https=)
GB (1) GB0007308D0 (https=)
HK (1) HK1052348B (https=)
HU (1) HUP0300591A3 (https=)
IL (2) IL150985A0 (https=)
MX (1) MXPA02009283A (https=)
MY (1) MY134189A (https=)
NO (1) NO20024321D0 (https=)
NZ (1) NZ521316A (https=)
PE (1) PE20011140A1 (https=)
PL (1) PL358253A1 (https=)
PT (1) PT1272489E (https=)
SI (1) SI1272489T1 (https=)
SK (1) SK13582002A3 (https=)
WO (1) WO2001070740A1 (https=)
ZA (1) ZA200206045B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007307D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
IL163779A0 (en) * 2002-03-15 2005-12-18 Pharmacia Corp Process for preparing crystalline form i of cabergoline
PL374503A1 (en) * 2002-03-15 2005-10-31 Pharmacia Corporation Process for preparing crystalline form i of cabergoline
IL155545A (en) 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
KR20060028761A (ko) 2003-05-08 2006-04-03 아이박스 파마슈티컬스 에스.알.오. 다형의 카베르골린
GB0409785D0 (en) * 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
GB0515430D0 (en) * 2005-07-27 2005-08-31 Resolution Chemicals Ltd Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
EP1925616A1 (en) * 2006-10-26 2008-05-28 LEK Pharmaceuticals D.D. Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline
EP1953157A1 (en) 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
US8637099B2 (en) * 2007-08-29 2014-01-28 Max Zeller Sohne Ag Use of Vitex agnus castus extracts for preparing a medicament
EP4074552B1 (en) * 2021-04-16 2024-04-03 Thermo King LLC Electrical connection unit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019322A1 (de) 1980-05-21 1981-12-03 Merck Patent Gmbh, 6100 Darmstadt Psychopharmakon sowie verwendung von adenosinderivaten
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) * 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB9205439D0 (en) * 1992-03-12 1992-04-22 Erba Carlo Spa Process for the synthesis of ergoline derivatives
WO1995005176A1 (en) 1993-08-18 1995-02-23 Alcon Laboratories, Inc. Use of ergoline derivatives for the treatment of glaucoma
JP2002509119A (ja) 1998-01-13 2002-03-26 アストラゼネカ ユーケイ リミテッド ドーパミン（Ｄ２）レセプターアゴニスト活性を有する化合物およびβ２−アドレナリンレセプターアゴニスト活性を有する化合物（Ｂ）を含有する薬学的組成物
JP2002507562A (ja) 1998-03-27 2002-03-12 ファルマシア・アンド・アップジョン・カンパニー レストレスレッグ症候群の治療におけるカベルゴリンの使用
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline

Also Published As

Publication number Publication date
NO20024321L (no) 2002-09-10
US6727363B2 (en) 2004-04-27
AU2005203071B2 (en) 2007-10-18
GB0007308D0 (en) 2000-05-17
EA200201016A1 (ru) 2003-02-27
ZA200206045B (en) 2003-07-29
US6953854B2 (en) 2005-10-11
PL358253A1 (en) 2004-08-09
EE200200545A (et) 2004-04-15
ATE250601T1 (de) 2003-10-15
AU780747B2 (en) 2005-04-14
HUP0300591A3 (en) 2009-01-28
HK1052348A1 (en) 2003-09-11
JP2003528100A (ja) 2003-09-24
AR032449A1 (es) 2003-11-12
EA005928B1 (ru) 2005-08-25
IL150985A0 (en) 2003-02-12
NZ521316A (en) 2004-05-28
AU2005203071A1 (en) 2005-08-11
EE05088B1 (et) 2008-10-15
BR0109507A (pt) 2002-12-10
CA2402836A1 (en) 2001-09-27
SI1272489T1 (en) 2004-02-29
CZ20023176A3 (cs) 2003-02-12
PE20011140A1 (es) 2001-11-01
MXPA02009283A (es) 2003-03-12
WO2001070740A1 (en) 2001-09-27
AU6211001A (en) 2001-10-03
DE60100858T2 (de) 2004-07-29
ES2208602T3 (es) 2004-06-16
US20040092744A1 (en) 2004-05-13
DE60100858D1 (de) 2003-10-30
KR100827558B1 (ko) 2008-05-07
HK1052348B (zh) 2005-09-16
EP1272489B1 (en) 2003-09-24
KR20020081587A (ko) 2002-10-28
DK1272489T3 (da) 2003-12-15
CN1188412C (zh) 2005-02-09
JP4184666B2 (ja) 2008-11-19
NO20024321D0 (no) 2002-09-10
CN1419554A (zh) 2003-05-21
EP1272489A1 (en) 2003-01-08
HUP0300591A2 (hu) 2003-07-28
IL150985A (en) 2007-03-08
PT1272489E (pt) 2004-02-27
US20030149067A1 (en) 2003-08-07
SK13582002A3 (sk) 2003-04-01

Similar Documents

Publication Publication Date Title
MY134189A (en) Process for preparing crystalline form i of cabergoline
BG105547A (en) Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
NZ334704A (en) Process for producing ecteinascidin compounds, intermediates and medicaments
IN2002CH00261A (https=)
AU7116691A (en) Process for the preparation of oxetanones
TW200632154A (en) Process for producing high quality large size silicon carbide crystals
AU3677989A (en) Methods for producing diorganodialkoxysilanes
PT1697326E (pt) Forma cristalina de composto quinolínico e processo para a sua produção
UA72895C2 (uk) Нова кристалічна модифікація n торасеміду
HU9301647D0 (en) Alkyl-hydroxy-alkyl-cellulose ethers containing sulfoalkyl group and method for producing them
MXPA04008935A (es) Procedimiento para la preparacion de la forma i cristalina de la cabergolina.
ZA200004720B (en) Process for preparing 5-hydroxybenzo (B) thiophene-3-carboxylic acid derivatives.
AU6578400A (en) Novel method for preparing benzoperhydroisoindole compounds
WO2001070694A8 (en) Amorphous torasemide modification
CZ20011915A3 (cs) Způsob výroby cyklenu
IL151168A (en) Process for producing a pentacyclic compound as an intermediate for the production of ecteinascidin and phthalascidin compounds
AU2001250429A1 (en) Method for producing 2-alkyl-3-chlorophenols
GB0108234D0 (en) Process for producing trunkamide A compounds
AU2005901A (en) Method for producing phosphonium phenolates
AU2003219423A1 (en) Process for the isolation of high purity crystalline citalopram base
WO2001066062A3 (en) Process for preparing pure crystalline lorazepam
WO2003087118A3 (de) Verfahren zur herstellung von beta-l-2'deoxy-thymidin
AU2001253602A1 (en) Synthesis of intermediates useful in preparing tricyclic compounds
HU9203344D0 (en) Method for producing substituted indoles
AU5925498A (en) Processes for producing 3-cyanopyridine from 2-methyl-1,5-pentanediamine